Sai Life Sciences Q1 FY27: Revenue up 13%, PAT rises 22% YoY

Results View source PDF Explain this filing

SAILIFE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-4.1%Reaction day

₹1414.00

prior close

₹1375.00

announcement price

After-mkt

timing

Nifty Smallcap 250market-0.0%-4.1% vs market

Pharmaceuticals peers, median of 167sector+0.3%-4.4% vs sector

On the reaction day the stock moved 4.1 pts less than Nifty Smallcap 250 and 4.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

-0.0

15m

+0.1

30m

+0.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-4.1-0.0-4.1+0.3-4.4

Next day

+1.1-0.1+1.1+0.7+0.4

+2.3+0.1+2.2+0.6+1.8

+3.5-0.1+3.6+0.2+3.3

+2.8+0.0+2.8+1.2+1.6

+2.4-0.4+2.8+0.2+2.2

+2.1-0.1+2.1+0.2+1.9

15d

+5.0+0.7+4.2+0.8+4.1

+12.4+0.7+11.8+2.4+10.0

+10.0-2.4+12.4+1.6+8.5

—————

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 167Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Sai Life Sciences posted solid Q1 FY27 results. Standalone revenue grew 13.2% YoY to Rs 547 crore, PAT up 22.2% at Rs 71 crore. Consolidated revenue rose 11.7% to Rs 554 crore, PAT up 21.2% to Rs 73 crore. Standalone basic EPS at Rs 3.36 vs Rs 2.80. Auditor Deloitte Haskins and Sells gave an unmodified review.

Likely market impact

Healthy double-digit growth in revenue and profit reflects strong momentum in the CRDMO business.